Irodalom:
1. Kaurah P, MacMillan A, Boyd N, et al: Founder and recurrent CDH1 mutations in families with hereditary
diffuse gastric cancer. JAMA 297:2360-2372, 2007
2. Norton JA, Ham CM, Van Dam J, et al: CDH-1 truncating mutation in the E-cadherin gene: an indication
for total gastrectomy to treat hereditary diffuse gastric cancer. Ann Surg 245:873-879, 2007
3. Seno H, Satoh K, Tsuji S, et al: Novel interleukon-4 and interleukin-1 receptor antagonist gene variations
associated with non-cardia gastric cancer in Japan: comprehensive analysis of 207 polymorphisms of
11 cytokine genes. J Gastroenterol Hepatol 22:729-737, 2007
4. Garza-Gonzalez E, Bosques-Padilla FJ, Mendoza-Ibarra SI, et al: Assessment of the toll-like receptor
4 Asp299Gly, Thr399IIe and interleukin-8 -251 polymorhisms in the risk for the development of distal
gastric cancer. BMC Cancer 7:70, 2007
5. Loh JT, Torres VJ, Cover TL.: Regulation of Helicobacter pylori cagA expression in response to salt.
Cancer Res 67:?4709-4715, 2007
6. Leal lMF, Lima EM, Silva PN, et al: Promoter hypermethylaltion of CDH1, FHIT, MTAP and PLAGL1
in gastric adenocarcinoma in individuals from Northern Brazil. World J Gastroenterol 13:2568-2574, 2007
7. Mitsui F, Dobashi Y, Imoto I, et al: Non-incidental coamplification of Myc and ERBB2, and Myc and
EGFR, in gastric adenocarcinoma. Mod Pathol 20:622-631, 2007
8. Yap YL, Zhang XW, Smith D, et al: Molecular gene expression signature patterns for gastric cancer
diagnosis. Comput Biol Chem 31:275-287, 2007
9. Guan-Zhen Y, Ying C, Can-Rong N, et al: Reduced protein expression of metastasis-related genes
(nm23, KISS1, KAI1 and p53) in lymph node and liver metastases of gastric cancer. Int J Exp Pathol
88:175-183, 2007
10. Zheng HC, Tsuneyama K, Takahashi H, et al: Aberrant Pim-3 expression is involved in gastric
adenoma-adenocarcinoma sequence and cancer progression. J Cancer Res Clin Oncol, 2007
A gyomor 165
11. Lee JH, Kim SH, Wang LH, et al: Clinical significance of CD99 down-regulation in gastric adenocarcinoma.
Clin Cancer Res 13:2584-2591, 2007
12. Kim JH, Kim MK, Lee HE, et al: Constitutive phosphorylation of the FOXO1A transcription factor as
a prognostic variable in gastric cancer. Mod Pathol 20:835-842, 2007
13. Takahashi H, Murai Y, Tsuneyama K, et al: High labeling indices of cdc25B is linked to progression of
gastric cancers and associated with a poor prognosis. Appl Immunohistochem Mol Morhol
15:267-272, 2007
14. Xing X, Chen J, Chen M.: Expression of CDC25 phosphatases in human gastric cancer. Dig Dis Sci , 2007
15. Yi KD, Kyoon JJ, Kyu PY, et al: E-cadherin expression in early gastric carcinoma and correlation with
lymph node metastasis. J Surg Oncol 96:429-435, 2007
16. Gao ZL, Zhang C, Du GY, Lu ZJ.: Clinical significance of changes in tumor markers, extracellular matrix,
MMP-9 and VEGF in patients with gastric carcinoma. Hepatogastroenterology 54:1591-1595, 2007
17. Dai N, Bao Q, Lu A, Li J.: Protein expression of osteopontin in tumor tissues is an independent prognostic
indicator in gastric cancer. Oncology 72:89-96, 2007
18. Wu CY, Wu MS, Chiang EP, Wu CC, Chen YJ, Chen CJ, Chi NH, Chen GH, Lin JT.: Elevated plasma
osteopontin associated with gastric cancer development, invasion and survival. Gut 56:782-789, 2007
19. Song SY, Son HJ, Kim MH, Nam ES, Rhee JC, Park C.: Prognostic significance of maspin expression
in human gastric adenocarcinoma. Hepatogastroenterology 54:973-976, 2007
20. Yang YH, Deng H, Li WM, et al: Identification of matrix metalloproteinase 11 as a predictive tumor
marker in serum based on gene expression profiling. Clin Cancer 14:74-81, 2008
21. Lee J, Park CK, Park JO, et al: Impact of E2F-1 expression on clinical outcome of gastric adenocarcinoma
patients with adjuvant chemoradiation therapy. Clin Cancer Res 14:82, 2008
22. Liu B, Wei J, Zou Z, et al: Polymorphism of XRCC1 predicts overall survial of gastric cancer patients
receiving oxaliplatin-based chemotherapy in Chinese population. Eur J Hum Genet 2007
23. Kono K, Takahashi A, Ichihara F, et al: Impaired antibody-dependent cellular cytotoxicity mediated by
herceptin in patients with gastric cancer. Cancer Res 62:5813-5817, 2002
